| Tavneos (avacopan) / Amgen |
| Not yet recruiting | 4 | 160 | Japan | Avacopan, prednisolone and rituximab, Prednisolone and rituximab | Chiba University, Kissei Pharmaceutical Co., Ltd., International University of Health and Welfare | ANCA Associated Vasculitis (AAV) | 03/27 | 09/28 | | |
NCT06072482: A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis |
|
|
| Recruiting | 4 | 300 | US | Avacopan, CCX168, Placebo, Standard of Care | Amgen | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | 10/31 | 10/31 | | |
NCT06321601: Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV. |
|
|
| Recruiting | 3 | 20 | US | Avacopan, AMG 569 | Amgen | Vasculitis | 07/30 | 07/30 | | |
NCT06676579: Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN) |
|
|
| Not yet recruiting | 2 | 16 | US | Avacopan, Tavneos, Prednisone, Methylprednisolone (drug), Prednisolone | Mayo Clinic | IgA Nephropathy (IgAN) | 03/28 | 03/29 | | |
NCT05984251: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants |
|
|
| Completed | 1 | 48 | Europe | CCX168, Placebo | Amgen | Vasculitis, Systemic Lupus Erythematosus (SLE) | 09/10 | 04/11 | | |
NCT06004960: A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants |
|
|
| Completed | 1 | 6 | US | [14C]CCX168 | Amgen | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | 12/14 | 12/14 | | |
NCT05988021: A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168 |
|
|
| Completed | 1 | 16 | US | CCX168 | Amgen | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | 02/16 | 05/16 | | |
NCT06004947: A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications |
|
|
| Completed | 1 | 32 | US | CCX168, Midazolam, Celecoxib, Itraconazole, Rifampicin | Amgen | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | 03/16 | 06/16 | | |
NCT05988008: A Study of CCX168 in Japanese and Caucasian Healthy Adult Males |
|
|
| Completed | 1 | 80 | Japan | CCX168, Avacopan, Placebo | Amgen | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | 01/18 | 09/18 | | |
NCT06004934: A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment |
|
|
| Completed | 1 | 24 | US | Avacopan, CCX168 | Amgen | Hepatic Impairment | 09/18 | 09/18 | | |
NCT05988034: A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants |
|
|
| Completed | 1 | 58 | US | Avacopan, Moxifloxacin, Placebo for avacopan, Placebo for moxifloxacin | Amgen | Electrocardiography | 01/20 | 03/20 | | |
NCT06207682: Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Single Dose of Simvastatin |
|
|
| Completed | 1 | 32 | US | Avacopan, CCX168, Simvastatin | Amgen | Healthy Volunteers | 08/22 | 08/22 | | |
2023-000381-34: Study in healthy adults to explore a children's liquid formulation compared to Avacopan 10 mg capsule adult formulation |
|
|
| Not yet recruiting | 1 | 31 | US | Avacopan, CCX168, Capsule, Oral liquid | ChemoCentryx, ChemoCentryx | Anti-Neutrophil Cytoplasmic Antibody associated vasculitis, ANCA-associated vasculitis, Body processes [G] - Immune system processes [G12] | | | | |
NCT06468826: A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD) |
|
|
| Completed | 1 | 13 | US | Avacopan, Tavneos, AMG 569, CCX168 | Amgen | End-Stage Renal Disease (ESRD) | 10/24 | 10/24 | | |
NCT06758271: Special Drug Use-results Survey for Long-term Use（Avacopan） |
|
|
| Recruiting | N/A | 250 | Japan | Avacopan | Kissei Pharmaceutical Co., Ltd. | Microscopic Polyangiitis (MPA), Granulomatosis With Polyangiitis (GPA) | 05/28 | 05/28 | | |
| Recruiting | N/A | 100 | Europe | | Leiden University Medical Center, University of Udine, University of Modena and Reggio Emilia, Hospital Universitari de Bellvitge, ZOL Hospital Genk Belgium | ANCA Associated Vasculitis | 01/26 | 12/26 | | |
| Recruiting | N/A | 500 | Europe | | Vifor Fresenius Medical Care Renal Pharma | ANCA-associated Vasculitis | 12/30 | 12/30 | | |
